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Abstract 
Identifying targets that are exposed on the plasma membrane of tumor cells, but expressed 
internally in normal cells, is a fundamental issue for improving the  specificity and efficacy of 
anticancer therpeutics. Using blind cell SELEX (Systemic Evolution of Ligands by EXponetial 
enrichment) which is untargeted SELEX, we have identified an aptamer, P15, which specifically 
bound to the human pancreatic adenocarcinoma cells. To identify the aptamer binding plasma 
membrane protein, liquid chromatography tandem mass spectrometry (LC-MS/MS) was used. The 
results of this unbiased proteomic mass spectrometry approach identified the target of P15 as the 
intermediate filament vimentin, biomarker of epithelial mesenchymal transition (EMT), which is 
an intracellular protein but is specifically expressed on the plasma membrane of cancer cells. As 
EMT plays a pivotal role to transit cancer cells to invasive cells, tumor cell metastasis assays were 
performed in vitro. P15 treated pancreatic cancer cells showed the significant inhibition of tumor 
metastasis. To investigate the downstream effects of P15, EMT related gene expression analysis 
was performed to identify differently expressed genes (DEGs). Among five DEGs, P15 treated 
cells showed the down-regulated expression of matrix metallopeptidase 3 (MMP3), which is 
involved in cancer invasion. These results, for the first time, demonstrate that P15 binding to cell 
surface vimentin inhibits the tumor cell invasion and is associated with reduced MMP3 expression. 
Thus, suggesting that P15 has potential as an anti-metastatic therapy in pancreatic cancer. 
 
Implications: This study reveals that anti-vimentin RNA aptamers selected via blind-SELEX 
inhibits the tumor cell metastasis. 
 
Introduction 
Aptamers, which are small single-stranded and structured nucleic acids, are powerful and 
emerging molecular tools for identifying biomarkers in cancer, as they can be selected to recognize 
a variety of targets including proteins, cultured cells, and whole organisms (1-6). Aptamers are 
generated by Systematic Evolution of Ligands by EXponential enrichment (SELEX) and hold 
their three-dimensional structures using well-defined complementary nucleic acid sequences (7,8). 
Because aptamers adopt complex structures, they can bind targets with high affinity and specificity 
and offer significant advantages over antibodies; better structural stability, low toxicity, low 
immunogenicity, and greater safety (7,8).  
Potential aptamer targets that are selectively expressed on the plasma membrane of cancer 
cells can be used to further understanding of tumor development and to develop improved targeted 
therapeutics. Ever since Berezovski et al. initiated aptamer-facilitated biomarker discovery 
(AptaBiD) (9), the identification and validation of biomarkers for therapeutics and the diagnosis 
of cancer has rapidly progressed; example biomarkers include: heat-shock protein 70 (HSP70) 
(10,11), heat-shock protein 90 (HSP90) (12,13), glucose-regulated protein 78 (GRP78) (14,15), 
vimentin (16), nucleolin (17,18), feto-acinar pancreatic protein (FAPP) (19), alkaline phosphatase 
placental-like 2 (ALPPL-2) (20), siglec-5 (21), stress-induced phosphoprotein 1 (STIP1) (22), and 
protein tyrosine kinase 7 (PTK7) (23). In pancreatic cancer, alkaline phosphatase placental-like 2 
(ALPPL-2) and cyclophilin B have also been reported to be novel candidate biomarkers (20,24).  
Pancreatic cancer is known to be one of the most deadly cancers and ranked as the fourth 
cause of cancer related death in both Europe and United States (25,26). Overall survival remains 
poor either in metastatic disease or in patients with early-stage disease (27). Mortality rate remains 
high because most patients are diagnosed with metastatic stage of disease at first diagnosed. 
Pancreatic metastases can arise in any organ site, but are mostly detected in abdominal sites. In an 
autopsy series, the liver is found to be the most common site of metastasis, followed by the 
peritoneum and lung (28,29).  Still, metastasis is the major cause of mortality in pancreatic cancer 
patients.  
Over past years, great efforts have made to develop therapeutics to improve the mortality 
rate. However, there has been limited progress in therapeutic options for metastatic pancreatic 
cancer, and traditional chemotherapy outcomes, even though improved, are still disappointing. In 
this study, to select cancer specific biomarkers for increasing therapeutic intervention, blind cell-
SELEX was employed against PANC-1 cells and liquid chromatography tandem mass 
spectrometry (LC-MS/MS)  was used to identify the aptamer binding ligand. 
 
Materials and Methods 
Chemicals 
Ultra-purified (Milli-Q) water, Acetonitrile (CH3CN, Burdick and Jackson HPLC grade), 
Ammonium bicarbonate (NH4HCO3, Sigma), Dithiothreitol (DTT, Sigma), Iodoacetamide (IAA, 
Sigma), Trypsin (Promega modified trypsin, sequencing grade), Trifluroacetic acid (TFA, Sigma).  
 
Blind SELEX (Naïve whole-Cell SELEX) 
The following cell lines were purchased from the American Type Culture Collection 
(ATCC) for use as targets for SELEX and internalization assays: PANC-1 (CRL-1469), CFPAC-
1 (CRL-1918), MIA PaCa-2 (CRL-1420), BxPC-3 (CRL-1687), and AsPC-1 (CRL-1682). Huh-7 
cells were purchased from Japanese Collection of Research Bioresources (JCRB). Cells were 
cultured according to the cell bank’s instructions.  
The SELEX cycle was performed basically as described by Tuerk and Gold (8) with few 
modifications which was carried out essentially as described (30).  
  
Flow cytometry-based binding assays 
  Aptamer binding was also assessed by flow cytometry as described previously (30). To 
determine the apparent dissociation constant (KD) of aptamers to PANC-1 cells, the mean 
fluorescence intensity (MFI) was calculated for each concentration and for the unselected library 
controls. The values for the controls were considered to be background fluorescence and were 
subtracted from the values for the aptamers, as previously described by Sefah et al. (31). The 
dissociation constants were calculated using a one-site binding model. Non-linear curve regression 
was performed using Graph Pad Prism (GraphPad Software, La Jolla, California, USA).  
 
Live-cell confocal imaging  
The aptamer internalization assay was determined described in previous studies (30). For 
the time-course internalization assay, 1 × 105 cells were seeded in 35 mm glass-bottom dishes 
(MatTek, MA, USA) and grown in medium for 24 hrs. Cy3 labeled P15 were added to the cells at 
200 nM of final concentration and incubated for 30 minutes, 1 hours, 2 hours, 3 hours and 4 hours. 
Seven to eleven different locations of images were taken at each time points. Based on the Cy3 
intensity on cells, the percentage was calculated. 
 
 Affinity purification of target membrane proteins and protein digestion 
Biotinylated aptamers, together with associated protein complexes, were immobilized 
using a pull-down process. SELEX-selected RNA aptamers and control RNAs were labelled with 
biotin at their 3’ ends. Target membrane proteins were isolated using procedures described by 
Daniels et al. (4). In-gel digestion was used for protein purification and analyzed by mass 
spectrometry for peptide fingerprinting. After polyacrylamide gel electrophoresis (SDS-PAGE), 
aptamer-retrieved protein bands were excised and in-gel digested (32).  
 
 Liquid chromatography Tandem MS/MS (LC-MS/MS) Q-TOF 
An Agilent 6520 Q-TOF mass spectrometer equipped with a Chip Cube source was used 
for LC-MS/MS analyses. A C18 chip with a 43mm analytical column and a 40nl trapping column 
(ProtID-Chip-43, Agilent G4240-62005) was used. Digested samples (10-15 µl) were loaded onto 
the column at 6 µl/minute in 99% Buffer A (0.1% Formic Acid in water)/1% Buffer B (0.1% 
Formic Acid in Acetonitrile) with an extra 8 µl wash volume. The gradient was from 3% to 35% 
Buffer B over 8 minutes and then 35% to 90% Buffer B over 1 minute. The total run time, including 
injection, was 15 minutes. The voltage was adjusted to the 1850V to 2000V range. The X! Tandem 
search engine (http://www.thegpm.org/TANDEM/index.html) was used to search the peptide 
MS/MS spectrum. The dataset was then processed using the Scaffold program 
(http://www.proteomesoftware.com) to visualize the results. SWISS Prot or NCBI were used to 
obtain the detailed protein annotation.  
 
Competition assays for validation of target 
For the aptamer-antibody competition assay, Cy3-labeled P15 aptamer was used to 
compete with vimentin antibodies (Sigma, V6630). The cells (1 × 105) were seeded in 35 mm 
glass-bottom dishes (MatTek, Ashland, MA, USA) and grown in medium for 24 hours. Cells were 
preincubated with vimentin antibodies, at 1 M, for 20 minutes before Cy3-labeled P15, at 200 
nM of final concentraion, was added. The cells were incubated for 2 hours at 37 °C. The images 
were taken using a Zeiss LSM 510 Meta Inverted 2-photon confocal microscope system using a 
C-Apo 40x/1.2NA water immersion objective. The arbitrary fluorescence intensity was quantified 
in the presence of vimentin antibodies competitors using confocal microscopy and analyzed 
statistically. Student’s t test was used for statistical significance analysis (P<0.05). 
For competition assay by flow cytometry, PANC-1 cells were detached using Accutase 
(Sigma-Aldrich), washed with DPBS, and suspended in binding. Next, PANC-1 cells were 
preincubated with vimentin antibodies, at 1 M, for 20 minutes on ice. After preincubation with 
vimentin antibodies, Cy3-labeled aptamers at 200 nM of final concentration were added and 
incubated with 2 × 105 cells for 30 minutes on ice. Cells were washed with DPBS three times and 
immediately analyzed by Fortessa flow cytometry (BD Biosciences, San Jose, CA). 4’6’-
diamidino-2-phenylindole (DAPI) (1µg/ml) was used to identify and exclude dead cells.  Data 
were analyzed with FlowJo software (FlowJo, Ashland, OR).  
 
Co-localization assay on live cells 
The cells (1 × 105) were seeded in 35 mm glass-bottom dishes (MatTek, Ashland, MA, 
USA) and grown in medium for 24 hours. Cells were incubated with Cy3-labeled P15 at 500 nM 
of final concentration, vimentin antibodies at 1:1000 dilution with anti-mouse Alexa Fluor 488 
antibodies at 1:2000 dilution for 1 hour at 37°C.  After washing with DPBS three times, the images 
were taken using a Zeiss LSM 880 confocal laser scanning microscope with Airyscan using a C-
Apo 62x/1.2NA water immersion objective. 
 
Biosensor assay 
The Biacore T100 (GE Healthcare, Uppsala, Sweden) was used to monitor label-free the aptamer–
vimentin interactions in real time. Biotinylated aptamers were coupled to a streptavidin-coated 
Biocore chip (SensorChip SA, BR-1003-98, General Electric Company) by an injection in binding 
buffer at concentration of 25 µg/mL at 10 µL/min. To measure binding kinetics, five concentration 
of vimentin protein were injected at a flow rate of 10 µL/min.  After binding, the surface was 
regenerated by injecting 50 mM NaOH at flow rate of 15 µL per minutes for 20 seconds.  Data 
from the control surface were subtracted. BIAevaluation software (GE Healthcare) was used for 
analysis. The binding data were fit to a 1:1 binding with a mass transfer model. 
 
Tumor cell migration assay 
Wound healing assays were performed with PANC-1 cells as described previously (33). 
Briefly, 1x106 PANC-1 cells were seeded in 35mm dishes and grown into a monolayer culture 
with 100% confluency. After scratching through the monolayer with a pipette tip, media were 
replaced with DMEM. 3000 nM of final concentration of folded P15 was added into media after 
scratching. The images were taken at 12hrs, 18hrs and 24hrs. Image Pro Premier v9.2 (Media 
Cybernetics, Rockville, MD) was used to quantify the wound distance by first making a calibration 
from an image of a stage micrometer. The calibration was applied to the images in the wound 
healing assay so that the distance could be reported in microns. In Image Pro Premier the wound 
distance was measured using the Line Tool in Measurements and the values were exported to 
Microsoft Excel for statistical analysis.       
 
Tumor cell invasion assay 
Tumor cell invasion assay was performed using the IncuCyte live-cell imaging system 
(ESSEN Bioscience) described previously (34). Cells were plated in IncuCyte ClearView 96-well 
cell migration plates for direct visualization of cell migration using phase-contrast. Cells were 
added to the top chamber of the ClearView plate and allowed to settle at ambient temperature with 
or without compounds. Images were taken for 2 days.  20% FBS was used as chemoattractant for 
positive control. Integrated metrics quantified the chemotactic response using 1,000 cells per well. 
Data was normalized with negative control. Each group is quadruplicate. Student’s t test was used 
for statistical significance analysis.   
 
Serum stability assay 
P15 was folded in folding buffer and incubated at 37 oC with the same volume of 100 % 
human serum or 100 % mouse serum, which is at the final concentration of 50 %. At each time 
points of 0, 0.5, 1, 2, 3, 4, 5, 6, 24, 48 hours, 10 μL of P15 was mixed with denature gel loading 
dye. 10 % denature PAGE gel was used to run the samples. Quantification of the bands was 
performed using Biorad Image Lab software. The aptamer half-lives were calculated by fitting the 
curve to the non-linear one-phase decay model using Graph Pad Prism. 
 
Gene expression analysis 
1 × 105 cells were seeded in 6 well plates one day before the treatment. 1 µM of P15 was 
incubated in cells for 48hrs. Total RNA was extracted and converted to cDNA by iScript reverse 
transcriptase (Bio-Rad, CA). Qiagen EMT RT2 profiler PCR array was used to analysis EMT 
related gene expression. 
 
Relative gene expression analysis by qPCR 
For analyzing gene down regulation, PANC-1, Mia PaCa-2 and BxPC-3 cells were seeded 
into 24-well plates at a density of 1 × 105 cells per well. P15 or irrelevant aptamer were added 
directly to the cells, in triplicate, at a final concentration of 1 µM. Total RNA was extracted 
(RNeasy mini kit, Qiagen) and converted to cDNA (iScript reverse transcriptase®, Bio-Rad, CA). 
The target cDNA was amplified by real-time PCR (SsoAdvanced Universal SYBR® Green 
Supermix, Bio-Rad, CA). Hypoxanthine-guanine phosphoribosyltransferase (HPRT) was used the 
reference gene to normalize. The 2-ΔΔCT was used for the relative quantification analysis. 
 
Cell proliferation assay 
To determine the inhibition of cell proliferation, 5 × 103 cells per well of  PANC-1, Mia 
PaCa-2 and BxPC-3 cells were seeded in 96-well plates at triplicates and grown in appropriate 
media for 24 h. P15 and irrelevant aptamer were added to cells at 1 µM and harvested them at 12 
hrs, 24 hrs and 48 hrs.  Inhibition of cell proliferation was measured by MTT assay (Promega, 
Madison, WI) at the indicated time intervals. 
 
Results 
Naïve whole SELEX 
To find potential biomarkers for pancreatic cancer, untargeted SELEX, called blind 
SELEX, was performed on naïve whole cells. To allow pancreatic cancer specificity, another type 
of cancer cells, Huh7 (hepatocarcinoma cells) was used as negative cells to remove non-specific 
binding of aptamers as described previously (30). To increase the nuclease resistance, 2´F 
pyrimidine modified RNAs was used to construct RNA aptamer library pool by PCR and in vitro 
transcription (IVT) (Fig. 1A). After 14 rounds of SELEX, a highly enriched aptamer, P15, was 
selected: GGGAGACAAGAATAAACGCTCAAAGTTGCGGCCCAACCGTTTAATTCAGA 
ATAGTGTGATGCCTTCGACAGGAGGCTCACAACAGGC. Minimum energy structural 
analyses of P15 were carried out using NUPACK software (http://www.nupack.org) (Fig. 1B). As 
depicted, the calculated secondary structure of P15 contains several stem-loop regions.  
 
P15 aptamer shows pancreatic cancer specificity and internalizes into cells  
To determine the binding on PANC-1 cells, P15 interactions with PANC-1 cells, aptamer 
binding was assessed by flow cytometry. The flow cytometry analyses of P15 confirmed enriched 
cell surface binding to PANC-1 cells, compared to the initial non-selected RNA library. PANC-1 
cells treated with Cy3-labelled P15 aptamers demonstrated significantly higher levels of positively 
stained cells (Fig. 1C). The binding affinity (KD) of P15 to PANC-1 cells was determined to be 
16.05 nM (Fig. 1D). To verify the specificity of P15 to pancreatic cancer cells, a panel of four 
different pancreatic cancer cell lines (AsPC-1, CFPAC, MIA PaCa-2 and BxPC-3) was treated 
with Cy3-labelled P15 aptamer. Interestingly, punctate cytoplasmic staining was observed in 
pancreatic cancer cell lines, but no staining was observed in negative control cells (Huh7) (Fig. 
2A). The pattern of cytoplasmic staining is suggestive of endocytic internalization of aptamers. 
The internalization assay over time showed the increased the positive percentage and intensity on 
PANC-1 cells (Fig. 2B). 
 
P15 aptamer binds to tumor associated cell surface vimentin 
To identify the P15 binding ligand, cell membrane proteins were extracted and retrieved 
by biotinylated P15. The retrieved proteins were separated by SDS-PAGE followed by Coomassie 
staining to visualize the resolved protein bands (Fig. 3A). The highest matching peak retrieved 
from P15-treated cells matched a known peak for vimentin by LC-MS/MS spectrum (Fig. 3B right 
and left panel). To validate the LC-MS/MS results, a competition assay with vimentin antibodies 
was performed by live cell confocal and flow cytometry. Fluorescence intensity was measured by 
confocal microscopy. The antibodies to vimentin significantly reduced the binding of P15 to target 
cells, P<0.05 (Fig. 3C). Preincubation with anti-vimentin antibodies prevented the binding of P15 
on PANC-1 by flow cytometry (Fig. 3D). These results strongly suggest the P15 bound to plasma 
membrane expressing vimentin on cancer cells. To confirm the direct binding of P15 with vimentin, 
surface plasmon resonance (SPR) with recombinant proteins and the colocalization assay on live 
cells were performed. In SPR assay, the increase in response units (RUs) from the baseline was 
measured and the calculated KD by SPR was similar with the KD determined with flow cytometry 
(Fig. 3E). In the colocalization assay, colocalization of Alexa 488-vimentin and Cy3-P15 were 
apparent in structures that appear yellow (Fig. 3F left) and overlayed spectrum in line profiling 
(Fig. 3F right). The overlap coefficient R value showed between 0.93 to 0.82, indicating the highly 
correlated colocalization of P15 and vimentin (Fig. 3F).  
 
P15 aptamer inhibits the cell motility and invasiveness of pancreatic cancer cells 
Vimentin is related with epithelial mesenchymal transition (EMT) during tumor metastasis 
(35). Since both cell migration and invasion have decisive role in the dissemination of cancer cells 
and metastasis, we further investigated the cell motility and invasion in vitro. For the motility of 
pancreatic cancer cells, a classic wound healing assay in which the cell monolayer was scratched 
and cells migrating to the wound area were monitored at different time points. Compared with 
control, the cells treated with P15 showed a wider wound distance after wound generation, and 
took a longer time to fill in the wound area, indicating a defect in migration (Fig. 4A and B).  
Tumor migration assay was done using uncoated Boyden chamber to examine the in 
vitro invasion ability of tumor cells. Cells that migrated to the bottom of the transwells were 
directly quantified by visualization using phase-contrast. Compared with the control group, P15 
treated groups (3000 nM and 1000 nM for 24, 36 and 48hrs incubation) displayed significantly 
inhibited cell migration (Fig. 4C). Groups treated with lower levels of P15 (333 nM and 111 nM) 
displayed cell invasiveness statistically equivalent to control (Fig. 4C). These results strongly 
indicate the P15 inhibits the tumor cell invasion. To figure out the nuclease resistance of P15, the 
serum stability of P15 in human and mice was assessed.  Even though 2 F´ pyrimidine modified 
nucleotides was incorporated during the SELEX process to increase the nuclease resistance, the 
intensity of the band (representing the amount of intact aptamer) decreases with time, indicating 
degradation of the full-length of aptamer (Fig. 4D). The biological half-life of the P15 was about 
3.37 hours in mice serum and 20.7 minutes in human serum (Fig. 4E). 
 
P15 aptamer is associated with downregulation of MMP3 
As vimentin is a biomarker for EMT, to investigate the downstream effects of P15 in EMT, 
EMT related gene expression was analyzed by PCR array after treatment of P15 in PANC-1.  
Among 84 key EMT related genes, five genes were identified as differently expressed genes 
(DEGs). In five DEGs, VCAN (Versican) and COL1A2 (Collagen, Type I, Alpha 2) were up-
regulated. MMP3 (Matrix Metallopeptidase 3), IL1RN (Interleukin 1 Receptor Antagonist), and 
TWIST 1 (Twist Family BHLH Transcription Factor 1) were down-regulated compared with non-
treated control (Fig. 5A). MMP3, an upregulated gene in EMT, was interestingly down-regulated 
in P15 treated cells in this study. To confirm the gene expression analysis by PCR array, relative 
quantitative real-time PCR was performed again. The consistent down-regulation of MMP3 
showed in 24 hrs and 48 hrs after treatment of P15 (Fig. 5B).  
To determine the effect of tumor cell proliferation by P15, MTT assay was performed as 
indicated time intervals.  We observed that P15 did not inhibit the cell proliferation in MTT assay 
(Fig. 5C). 
 
Discussion 
Untargeted SELEX, also called “blind SELEX”, was employed to generate highly enriched 
RNA aptamers against pancreatic cancer cells. This strategy allows us to identify aptamers that 
bind specifically to PANC-1 cells. To identify aptamer binding ligands which might be used as 
potential biomarkers, the cell membrane was retrieved using affinity purification through the RNA 
aptamers. The aptamer-bound proteins were then identified by LC-MS/MS. Because LC-MS/MS 
does not require the samples be purified to a high degree of homogeneity (36) and works well as 
long as the target protein is a major component of the mixture (37), it the best choice in protein 
biomarker discovery. We have initiated this study to discover new biomarkers for pancreatic 
cancer. Unexpectedly, the binding cell surface target of P15 was determined the cell surface 
vimentin on cancer cells by LC-MS/MS. The direct binding of P15 with vimentin was measured 
with SPR (Fig. 3E). The colocalization of P15 with vimentin was confirmed intracellularly (Fig. 
3F), suggesting that the cell surface vimentin binding P15 aptamer is internalized into the 
pancreatic cancer cells. 
Vimentin belongs to the group of intermediate filament proteins, which forms the 
cytoskeleton and associates with the nucleus, mitochondria, and ER (38). Vimentin, intracellular 
EMT tumor cell marker, is recently discovered as a mislocalized protein on the surface of 
metastatic cancer (39). The recruitment of vimentin to the cell surface is mediated by β3 integrin 
(16). Vimentin protein expression show 3-fold higher in pancreatic cancer than its expression in 
other type of cancers including lung, colon, and ovarian (40). It is reported that the presence of 
vimentin-expressing in pancreatic cancer predicts a shorter postsurgical survival (41). Vimentin 
expression is also correlated with epithelial mesenchymal transition (EMT) during tumor 
progression and metastasis (42). Targeting mislocalized cancer surface proteins is greatly 
improved the therapeutic interventions without harming normal cells. For the therapeutic use of 
P15, we hypothesized that P15 might be associated with the loss of invasion capabilities in tumor 
cells. Because the transition of cancer cells to invasive cell type via EMT is widely accepted as a 
pivotal role in tumor metastasis (35). To determine the therapeutic effects of P15, the tumor cell 
metastasis assay were performed in vitro platform. As suggested by our hypothesis, P15 showed 
the significant inhibition of tumor cell metastasis (Fig. 4A, B and C).  However, P15 showed the 
lack of nuclease resistance in human and mice serum (Fig. 4D and E). As the aptamers can be 
reduced in size and be incorporated RNA analogues through chemical synthesis (43), to confer the 
nuclease resistance of P15 for in vivo assays and clinical trials, the truncation of P15 with 2´-O-
methyl modified nucleotides will be investigated in future studies. 
For further investigation of the downstream effects of P15 on EMT, 84 key genes involved 
in EMT were profiled using the Human Epithelial to Mesenchymal Transition (EMT) RT² PCR 
Array.  Among the five DEGs, interestingly, our data showed the down-regulated expression of 
MMP3 in P15 treated cells based on the results of gene expression analysis (Fig. 5A and B). 
Generally, MMP3 is an upregulated gene in EMT progression (44) and related to metastasis (45). 
For the biological functions, MMP3 modulates the tumor microenvironment and cancer cell 
invasion (44). It is also associated with poorer patient prognosis in pancreatic cancer (46). Our 
study suggest that P15 is associated with the downregulation of MMP3. In the MTT assay, P15 
did not inhibit the tumor cell proliferation, which is consistent with the reported results that tumor-
produced MMP3 does not affect in tumor growth (47). 
In summary, this is the first study to show that anti-vimentin aptamers inhibited tumor cell 
invasion and the downregulation of MMP3 is associated with it. Moreover, the anti-vimentin 
aptamer P15, might be an effective anti-metastatic drug for use in the treatment of pancreatic 
cancer. 
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FIGURE LEGENDS 
Figure 1.  Naïve cell SELEX and Binding affinity. A, Schematic untargeted live-cell SELEX 
procedures. The DNA library contained 40 nt of random sequences was synthesized and amplified 
by PCR. 2′F modified RNA aptamer library was synthesized throughout in vitro transcription. To 
remove non-specific binding, aptamer library pools were incubated on Huh7 cells as the negative 
cells. The supernatant was again incubated on PANC-1 cells for positive selection. Total RNA was 
extracted and amplified through polymerase chain reaction (PCR) and in vitro transcription (IVT). 
The RNA aptamer selection was repeated for 14 rounds of SELEX.  
B, P15 was selected from a randomized N40 RNA library, after 14 rounds of SELEX. The 
secondary structure of P15 was predicted using NUPACK software.  C, Cy3-labeled P15 aptamers 
(200 nM) were assessed for binding efficiency by flow cytometry in PANC-1 and control Huh7 
cells. Data show from triplicate experiments. Huh7 CC (Huh7 unstained cell control), PANC-1 
CC (PANC-1 unstained cell control), Huh7 Lib (Huh 7 staining control with a Cy3-labeled library), 
PANC-1 Lib (PANC-1 staining control with a Cy3-labeled library), Huh7 P15 (Huh7 stained with 
P15), PANC-1 P15 (PANC-1 stained with P15). D, The dissociation constant (KD) was measured 
by flow cytometry using increasing concentrations of Cy3-labeled aptamers (15.6 to 500 nM). 
Mean fluorescence intensity (MFI) was measured and calculated using a one-site binding model 
for non-linear regression. 
 
Figure 2. Internalization of P15. A, Cell internalization was assessed on live cells. The pancreatic 
cell lines PANC-1, AsPC-1, CFPAC-1, MIA PaCa-2, BxPC-3 and Huh7 were treated with 100 
nM of final concentration of the Cy3-labeled P15 aptamer and analyzed by confocal microscopy. 
All pancreatic lines show punctate regions of Cy3 labeling. The Huh7 negative cells showed 
negative staining.  Red: Cy3-labeled RNA. Blue: Hoechst 33342. Scale bar: 10 µm. B, Quantitative 
internalization assay over time in live cells. The PANC-1 were treated with 200 nM of final 
concentration of the Cy3-labeled P15 aptamer and incubated for the indicated time interval. The 
percentage of internalization was assessed by confocal microscopy in different locations at each 
time points (N=7-11).  
 
Figure 3. Tandem MS/MS spectra of aptamer binding ligand. A, Polyacrylamide gel 
electrophoresis (SDS-PAGE) was used to separate immobilized protein samples after pulldown 
with biotinylated P15 and negative control RNAs. Coomassie-stained gels M (Marker), total cell 
lysate (lane 1), P15 (lane 2), NC (irrelevant RNA, lane 3). Arrow indicates target. B, Peptide 
matching and MS/MS spectrum of P15 affinity-purified peptides. Inset: Amino acid sequence of 
the parent peptide showing b- and y-ion series coverage. Target epitopes are highlighted in yellow. 
C, An aptamer-antibody competition assay was used to validate the target. Cy3-labeled P15 
aptamer was used to compete with vimentin antibodies in PANC-1.  P15-VIM-NC; P15 treated 
without vimentin antibodies. P15-VIM-competition; P15 treated with vimentin antibodies. Bound 
P15 was calculated using fluorescence intensity (AU: arbitrary units). Student’s t test was used for 
the statistical significance analysis. (N=10) *: P≤0.05. D, Flow cytometry based competition assay. 
After preincubation with vimentin antibodies, Cy3-labeled aptamers at 200 nM of final 
concentration were added and incubated with 2 × 105 cells for 30 minutes on ice. Reduction of 
binding was observed in vimentin antibody treated group. P15-VIM-NC; P15 treated without 
vimentin antibodies. P15-VIM-competition; P15 treated with vimentin antibodies. E. The SPR 
sensorgrams of binding P15 with vimentin. For the binding assay of P15 aptamer–vimentin by 
SPR, the Biacore T100 was used to monitor label-free interaction of P15 with vimentin. The 
increase in response units (RUs) from the baseline was measured.  BIAevaluation software was 
used to measure the binding affinity. F, The Colocalization of P15 with vimentin on live cells. 
After co-incubation of P15 with anti-vimentin antibodies for 1 hour at 37 °C in PANC-1, 
colocalization of P15 with vimentin was analyzed with Zeiss LSM scanning microscopy with 
Airyscan. The correlation R value of Alexa 488 and Cy3 appearing yellow was indicated on left 
top corner in three different positions. Red: Cy3 labeled P15, Green: Anti-vimentin with Alexa 
488. Blue: Hoechst 33342. Scale bar: 5 µm. The colocalization of Alexa 488-vimentin and Cy3-
P15 appeared yellow (left) and overlayed spectrum in line profiling (right).  
 
Figure 4. Cell migration and invasion assays.  A, Phase contrast images of wound healing assay 
were taken at 0 h (immediately after scratching) and at the indicated time intervals in irrelevant 
aptamer (top panels) and the wound open in P15 treated cells (down panels). 3 µM of final 
concentration of folded P15 was added into media after scratching. Control (irrelevant aptamers) 
showed the wound closure at 20 hours. Scale bar = 100 µm. B, The results of wound healing assay 
represented the mean of three measures of each wounded area. Error bars indicate mean ± standard 
deviation (N=3). Student’s t test was used for the statistical significance analysis. *: P≤0.05. **: 
P≤0.01, ***: P≤0.001. C, Chemotaxis cell invasion assay by IncuCyte live-cell imaging system. 
Integrated metrics quantified the chemotactic response using 1,000 cells per well. Data was 
normalized to negative control. Each group is shown in quadruplicate. Student’s t test was used 
for the statistical significance analysis. *: P≤0.05. **: P≤0.01, ***: P≤0.001.  D, Serum stability 
of P15 in human and mice serum. Folded P15 was incubated in 50 % of human and mice serum 
for indicated time intervals at 37 °C and the aptamer samples were separated by denaturing PAGE 
gel electrophoresis.  E, The intact aptamer (%) was plotted as a function of the incubation time (0 
to 48 hours) and fitted using a non-linear one-phase decay model (GraphPad). 
 
Figure 5.  EMT-related gene profiling and cell proliferation assay. A, 84 key genes involved in 
EMT were profiled by the Human Epithelial to Mesenchymal Transition (EMT) RT² Profiler PCR 
Array. VCAN and COL1A2 were up-regulated. MMP3, IL1RN and TWIST 1 were down-
regulated in P15 treated PANC-1. B, Relative transcript expression for MMP3 mRNA was 
quantified by real-time PCR. HPRT was used for the housekeeping gene to normalize.  One way 
ANOVA test was used for the statistical significance analysis. *: P≤0.05. **: P≤0.01, ***: P≤0.001. 
C, Cell proliferation assay was performed by MTT assay.  No significant results have been 
observed. One way ANOVA test was used for the statistical significance analysis. 
 
